# Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis

> **NCT02643212** · PHASE3 · UNKNOWN · sponsor: **David Garcia Cinca** · enrollment: 160 (estimated)

## Conditions studied

- Cirrhosis

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02643212
- **Lead sponsor:** David Garcia Cinca
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2018-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02643212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02643212, "Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02643212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*